EUVIMEDEUVIMED entdecken
Crossref

Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases

Ofer Margalit, Sivan Lieberman, Ilanit Redinsky, Sharon Halparin, Nir Honig, Stephen Raskin, Maoz Ben-Ayun, Einat Shacham-Shmueli, Naama Halpern, Damien Urban, Aliza Ackerstein, Katerina Shulman und 12 weitere

Clinical Colorectal Cancer · 2023

DOI: 10.1016/j.clcc.2023.08.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2023. Verfasst von Ofer Margalit und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sheba Medical Center, Ramat Gan affiliated with Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Radiosurgery, Colorectal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Microsatellite stable metastatic colorectal cancer (MSS mCRC) is largely refractory to immune checkpoint inhibition. We hypothesized that a combination of intratumoral TLR9 agonist, radiosurgery and dual PD-1 and CTLA-4 blockade would induce a local focus of immune stimulation, evoking a systemic immune response. PATIENTS AND METHODS: In this phase I single-institution study, patients with MSS mCRC were treated with a priming dose of s.c vidutolimod, 3 intratumoral injections of vidutolimod and radiosurgery, combined with nivolumab and ipilimumab. Cytokine levels were measured at baseline and at 7 (± 2) weeks. Patients were accrued to 4 consecutive cohorts: (1) Safety run-in without radiosurgery, (2) Radiosurgery prior to intratumoral therapy, (3) Radiosurgery prior to intratumoral therapy with a condensed timeline, and (4) Radiosurgery to extrahepatic lesion following completion of intratumoral therapy. RESULTS: A total of 19 patients were accrued. Median age was 59 years (range 40-71), 68% were male, median number of previous systemic treatments was 3 (range 2-5). None of the patients responded, aside from 1 patient, attributed to high tumor mutational burden. Grade 3 liver toxicity was reported in 0%, 0%, 75%, and 17% in cohorts 1 to 4, respectively. Systemic levels of CXCL10 and IL-10 increased, with a median of 407 versus 78 pg/mL (P = .01), and 66 versus 40 pg/mL (P = .03), respectively. CONCLUSIONS: The combination of intratumoral vidutolimod, radiosurgery, nivolumab and ipilimumab was not found to be efficacious in MSS mCRC with liver metastases. The juxtaposition of liver irradiation and intratumoral vidutolimod injection was associated with high hepatic toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalRadiosurgeryColorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsLiver NeoplasmsHumansMaleAdultMiddle AgedAgedFemaleIpilimumabNivolumabMicrosatellite Repeats

Stichwörter der Autor:innen

ImmunotherapyIntratumoral injectionMetastatic colorectal cancerRadiotherapyToll-like receptor 9 agonist

Substanzen

IpilimumabNivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Medical Oncology, Sheba Medical Center, Ramat Gan affiliated with Tel Aviv University, Tel Aviv, Israel.
  • Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan affiliated with Tel Aviv University, Tel Aviv, Israel.
  • Department of Radiation Oncology, Sheba Medical Center, Ramat Gan affiliated with Tel Aviv University, Tel Aviv, Israel.
  • Department of Medical Oncology, Sheba Medical Center, Ramat Gan affiliated with Tel Aviv University, Tel Aviv, Israel; Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan affiliated with Tel Aviv Universit…
  • Department of Medical Oncology, Lady Davis Carmel Hospital, Haifa, Israel.
  • Department of Medical Oncology, Hillel Yaffe Medical Center, Hadera, Israel.

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Margalit, O., Lieberman, S., Redinsky, I., Halparin, S., Honig, N., Raskin, S., Ben-Ayun, M., Shacham-Shmueli, E., Halpern, N., Urban, D., Ackerstein, A., Shulman, K., Ben-Ami, E., Semenisty, V., Purim, O., Yarom, N., Golan, T., Boursi, B., Appel, S., …, & Lawrence, Y. R. (2023). Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2023.08.004

Vancouver

Margalit O, Lieberman S, Redinsky I, Halparin S, Honig N, Raskin S, et al. Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases. Clinical Colorectal Cancer. 2023. doi:10.1016/j.clcc.2023.08.004

BibTeX
@article{Margalit2023,
  author = {Margalit, Ofer and Lieberman, Sivan and Redinsky, Ilanit and Halparin, Sharon and Honig, Nir and Raskin, Stephen and Ben-Ayun, Maoz and Shacham-Shmueli, Einat and Halpern, Naama and Urban, Damien and Ackerstein, Aliza and Shulman, Katerina and Ben-Ami, Eytan and Semenisty, Valeriya and Purim, Ofer and Yarom, Nirit and Golan, Talia and Boursi, Ben and Appel, Sarit and Symon, Zvi and Berger, Raanan and Mauro, David and Krieg, Art M and Lawrence, Yaacov R},
  title = {Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases},
  journal = {Clinical Colorectal Cancer},
  year = {2023},
  doi = {10.1016/j.clcc.2023.08.004}
}
Kostenlos starten →